{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:25:05Z","timestamp":1775748305547,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2025.03.026","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T21:05:32Z","timestamp":1745355932000},"page":"440.e1-440.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["BCG response and oncological outcomes in high risk nonmuscle invasive bladder cancer following previously treated upper tract urothelial carcinoma: A propensity-matched analysis"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7806-9569","authenticated-orcid":false,"given":"Benjamin J.H.","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khi Yung","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julene","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung Wen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher W.S.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.P.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Y.S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Chong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Abern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Guang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Issue 1","key":"10.1016\/j.urolonc.2025.03.026_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"Vol. 84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euros.2023.01.004","article-title":"Bladder recurrence following upper tract surgery for urothelial carcinoma: a contemporary review of risk factors and management strategies","volume":"49","author":"Mertens","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0003","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0005","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting non muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.03.026_bib0006","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000524449","article-title":"Masatsugu Iwamura; patients with non-muscle-invasive bladder cancer previously treated with nephroureterectomy have a high risk of recurrence after Bacillus Calmette-Gu\u00e9rin Intravesical Instillation Therapy","volume":"68","author":"Maeyama","year":"2023","journal-title":"Chemotherapy"},{"issue":"9","key":"10.1016\/j.urolonc.2025.03.026_bib0007","doi-asserted-by":"crossref","first-page":"289.e7","DOI":"10.1016\/j.urolonc.2024.05.007","article-title":"Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma","volume":"42","author":"Massari","year":"2024","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.026_bib0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00345-012-0946-6","article-title":"Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours","volume":"31","author":"Yates","year":"2013","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.026_bib0009","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urolonc.2009.06.003","article-title":"Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance","volume":"29","author":"Az\u00e9mar","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 Classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"Issue 10","key":"10.1016\/j.urolonc.2025.03.026_bib0011","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eursup.2006.04.008","article-title":"Improving patient outcomes: optimal BCG treatment regimen to prevent progression in superficial bladder cancer","volume":"Vol. 5","author":"Lamm","year":"2006","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.026_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"5","key":"10.1016\/j.urolonc.2025.03.026_bib0014","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bju.14111","article-title":"Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma","volume":"121","author":"Miyake","year":"2018","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.03.026_bib0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6690643","article-title":"Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding","volume":"81","author":"Fadl-Elmula","year":"1999","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2025.03.026_bib0017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.urolonc.2022.11.001","article-title":"Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: a single institution series and systematic review","volume":"41","author":"Fontanet","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0018","doi-asserted-by":"crossref","unstructured":"Yoneyama T, Soma O, Suzuki Y, Yoneyama T, Mori K, Yamamoto H, et al. (2019). Clinical impact of Bacillus Calmette-Gu\u00e9rin (BCG) therapy on prognosis in patients with carcinoma in situ (CIS) of the upper urinary tract: a retrospective comparison with nephroureterectomy. 10.1200\/JCO.2019.37.7_SUPPL.417","DOI":"10.1200\/JCO.2019.37.7_suppl.417"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0019","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.urolonc.2020.01.008","article-title":"Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review","volume":"38","author":"Van Doeveren","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0020","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nature Comm"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0022","first-page":"e85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"17","author":"Kardos","year":"2016","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.urolonc.2025.03.026_bib0023","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","article-title":"Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma","volume":"23","author":"Catto","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.026_bib0024","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Gu\u00e9rin response in patients with T1G3 high-risk bladder tumours","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.03.026_bib0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clgc.2018.01.009","article-title":"High CDKN2A\/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma","volume":"16","author":"Breyer","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2025.03.026_bib0026","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/cells9081839","article-title":"Discovery of molecular DNA methylation-based biomarkers through genome-wide analysis of response patterns to BCG for bladder cancer","volume":"9","author":"Ilijazi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0027","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s13577-022-00789-z","article-title":"ELK1 suppresses SYTL1 expression by recruiting HDAC2 in bladder cancer progression","volume":"35","author":"Wang","year":"2022","journal-title":"Hum. Cell"},{"key":"10.1016\/j.urolonc.2025.03.026_bib0028","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Investig"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:43:00Z","timestamp":1748443380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1078143925001267"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG response and oncological outcomes in high risk nonmuscle invasive bladder cancer following previously treated upper tract urothelial carcinoma: A propensity-matched analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}